Please select the option that best describes you:
Do you consider MSI testing for mCRPC?
Based on 2-3% MSH2 mutation and 1% MLH1 mutation rates in metastatic disease regardless of castration sensitivity, should we be looking for this earlier in the disease course (before CRPC) to try to bring PD-1 earlier in therapy?
Answer from: Medical Oncologist at Academic Institution
I agree that data for response to immunotherapy in MMR-deficient (dMMR) prostate cancer is limited, and we estimate the rate of dMMR in prostate cancer to be low, in the 2-3% range. Nonetheless, based on responses in other dMMR tumors, pembrolizumab is now FDA approved for all dMMR/MSI-high unresect...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
In contrast to the state of molecularly targeted therapeutics in other solid tumors such as lung cancer and melanoma our current knowledge base in prostate cancer is really just getting started with encouraging early data with regards the frequency and ability to target DNA mismatch repair abn...